These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 13626994)
21. [Clinical pharmacology of the neuromuscular junction in myasthenia gravis. (Preliminary communication)]. Jurenić D; Jusić A Neurologija; 1978; 26(1-4):37-9. PubMed ID: 754038 [No Abstract] [Full Text] [Related]
22. [A serum factor blocking neuromuscular transmission in myasthenia gravis: electrophysiological study with intracellular microelectrodes (author's transl)]. Shibuya N Rinsho Shinkeigaku; 1978 Apr; 18(4):177-84. PubMed ID: 212240 [No Abstract] [Full Text] [Related]
23. Myasthenia gravis and atracurium. A case report. Macdonald AM; Keen RI; Pugh ND Br J Anaesth; 1984 Jun; 56(6):651-4. PubMed ID: 6326789 [TBL] [Abstract][Full Text] [Related]
24. Clinical Practice Guidelines for Sustained Neuromuscular Blockade in the Adult Critically Ill Patient. Murray MJ; DeBlock H; Erstad B; Gray A; Jacobi J; Jordan C; McGee W; McManus C; Meade M; Nix S; Patterson A; Sands MK; Pino R; Tescher A; Arbour R; Rochwerg B; Murray CF; Mehta S Crit Care Med; 2016 Nov; 44(11):2079-2103. PubMed ID: 27755068 [TBL] [Abstract][Full Text] [Related]
25. Neuromuscular function and plasma drug levels in pyridostigmine treatment of myasthenia gravis. Breyer-Pfaff U; Schmezer A; Maier U; Brinkmann A; Schumm F J Neurol Neurosurg Psychiatry; 1990 Jun; 53(6):502-6. PubMed ID: 2166138 [TBL] [Abstract][Full Text] [Related]
26. The influence of normal human serum and its ultrafiltrate on neuro-muscular transmission. Sandweg R; Kruckenberg P Electroencephalogr Clin Neurophysiol; 1968 Oct; 25(4):397. PubMed ID: 4176564 [No Abstract] [Full Text] [Related]
28. Abnormalities in neuromuscular transmission, with special reference to myasthenia gravis. GROB D; HARVEY AM Am J Med; 1953 Nov; 15(5):695-709. PubMed ID: 13104438 [No Abstract] [Full Text] [Related]
29. Difference in sensitivity to vecuronium between patients with ocular and generalized myasthenia gravis. Itoh H; Shibata K; Nitta S Br J Anaesth; 2001 Dec; 87(6):885-9. PubMed ID: 11878691 [TBL] [Abstract][Full Text] [Related]
30. Myasthenia gravis. III. Lack of inhibitory action of fractionated thymus extracts. ZACKS SI Proc Soc Exp Biol Med; 1958 Dec; 99(3):574-5. PubMed ID: 13614427 [No Abstract] [Full Text] [Related]
31. Evaluation of atracurium in myasthenic patients undergoing thymectomy. Huang YG; Luo AL; Luo LK Proc Chin Acad Med Sci Peking Union Med Coll; 1990; 5(2):102-6. PubMed ID: 2243832 [TBL] [Abstract][Full Text] [Related]
32. Plasma concentration of pyridostigmine and effects in myastenia gravis. Chan K; Calvey TN Clin Pharmacol Ther; 1977 Nov; 22(5 Pt 1):596-601. PubMed ID: 199393 [TBL] [Abstract][Full Text] [Related]
33. Studies in neuromuscular function. II. Effects of nerve stimulation in normal subjects and in patients with myasthenia gravis. GROB D; HARVEY AM; JOHNS RJ Bull Johns Hopkins Hosp; 1956 Sep; 99(3):125-35. PubMed ID: 13364528 [No Abstract] [Full Text] [Related]
35. Studies on the reaction of the isolated phrenic nerve diaphragm preparation of various species to certain agents causing a neuromuscular block. BERGH NP Scand J Clin Lab Invest; 1953; 5 Suppl 7():5-29. PubMed ID: 13075957 [No Abstract] [Full Text] [Related]
36. Motor end plate changes in myasthenia gravis. CHURCHILL-DAVIDSON HC Am J Phys Med; 1959 Aug; 38():159-62. PubMed ID: 13810230 [No Abstract] [Full Text] [Related]
37. Some effects of extracts of thymus glands removed from patients with myasthenia gravis. WILSON A; OBRIST AR; WILSON H Lancet; 1953 Aug; 265(6782):368-71. PubMed ID: 13085784 [No Abstract] [Full Text] [Related]
38. [The action of potassium on neuromuscular transmission in myasthenia gravis]. DESMEDT JE J Physiol (Paris); 1955; 47(4):655-7. PubMed ID: 13307448 [No Abstract] [Full Text] [Related]